print this page 
text size
SPRYCEL Mechanism of Action
The first and only registered combined BCR-ABL
and SRC kinase inhibitor1,19,20
SPRYCEL targets other oncogenic pathways, such as c-KIT, ephrin receptor kinases, and PDGF ß-receptors, and is 325 times more potent than imatinib in vitro in BCR-ABL inhibition assays. SPRYCEL is active against all BCR-ABL mutations, except T315I.
1,21
Disclaimer: This is an international Web site for SPRYCEL® (dasatinib) and is intended for healthcare professionals outside the U.S.
If you are a U.S. resident, please visit www.SPRYCEL.com.
If you are not a healthcare professional, please visit www.BMS.com.
The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located or practice.